This HTML5 document contains 95 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n11http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n4https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q58204787
rdf:type
wikibase:Item
schema:description
im Oktober 2011 veröffentlichter wissenschaftlicher Artikel наукова стаття, опублікована в жовтні 2011 wetenschappelijk artikel scholarly article by Takao Koike et al published 13 October 2011 in Modern Rheumatology
p:P577
wds:Q58204787-3476E323-CEB5-4EE9-9C3A-06062E4EE7DA
wdt:P577
2011-10-13T00:00:00Z
p:P2888
wds:Q58204787-31287EF3-6CE6-4CC8-B3FD-D7125AC72824
wdt:P2888
n4:s10165-011-0541-5
p:P2860
wds:Q58204787-0FE86C80-E8BB-49BF-BF19-E937F4138B86 wds:Q58204787-3091CEF9-1D17-4BD1-BE78-C77AB5ABB41A wds:Q58204787-3EAFAA98-147C-4186-AC15-1FAD0A9C9F42 wds:Q58204787-49C4367F-DE2E-4995-B50A-DADB56F86598 wds:Q58204787-50D12D38-ACFF-4389-A358-F86E56555219 wds:Q58204787-5D3098AA-ADF3-4F76-82CC-33CF6D1E10A8 wds:Q58204787-6B644FBC-AF2E-4B30-B391-4897336C6A4B wds:Q58204787-77096B13-83E8-4FF4-8F85-76943725C96C wds:Q58204787-8999A148-54FA-4EDB-BCF2-720B883D70E5 wds:Q58204787-92B52873-1A61-4F38-8EA1-3C3C3DA35DD0 wds:Q58204787-C1D18DDF-0390-49F9-8361-7EFD65F479EC wds:Q58204787-C91E2D9F-514D-4D32-9337-9643FBB90ACA wds:Q58204787-CFB20699-6086-4060-8E4A-AA9B2DE8F137 wds:Q58204787-D4D39ECE-13BF-486B-8FDA-83E801FF8C5A wds:Q58204787-D9979D5E-8913-45C7-BB12-C6EA37711B3D wds:Q58204787-DB4B5BFE-BB07-4281-9222-5C18EE8BB283 wds:Q58204787-DC013882-0649-4611-91AC-864CF6435ED7 wds:Q58204787-E5AEAF77-1B09-4B88-BB85-7E5E7867B3C0 wds:Q58204787-E8F4D747-8C61-4E23-BF39-A38354968882
wdt:P2860
wd:Q44266273 wd:Q34019267 wd:Q58204942 wd:Q37793831 wd:Q44952372 wd:Q46919825 wd:Q35637322 wd:Q40629895 wd:Q33819684 wd:Q35554834 wd:Q37404893 wd:Q44579735 wd:Q56969723 wd:Q34216770 wd:Q58204891 wd:Q34923104 wd:Q38382764 wd:Q35018415 wd:Q36013844
p:P2093
wds:Q58204787-1511F45A-39FC-4402-8EFA-23D5D68A4B3F wds:Q58204787-0400CCAD-4118-45A7-A109-9EDEB6D32249 wds:Q58204787-2FDC51C6-4BA6-4EF5-9472-47AB5EDD89A5 wds:Q58204787-EE6A3185-0475-43BC-8FAA-006FEFAF7EED wds:Q58204787-DCD7C21B-1B29-45EE-B91B-615B58BA9ECD wds:Q58204787-D43EEEE9-7B4E-45AD-8891-D23D9EC585F4
wdt:P2093
Tsutomu Takeuchi Naoki Ishiguro Shuji Takei Yoshiya Tanaka Shigeko Inokuma Masayoshi Harigai
rdfs:label
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients
skos:prefLabel
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients
schema:name
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients
p:P50
wds:Q58204787-F3CD6780-AF18-4E7B-A32F-D5A61AAD6843 wds:Q58204787-73BF3773-A548-45BE-B85E-378295608B14
wdt:P50
wd:Q88712489 wd:Q73731383
p:P1476
wds:Q58204787-1AF2CCBB-7CB1-40B0-9859-A7C79E540A08
wdt:P1476
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients
p:P304
wds:Q58204787-46700E22-382C-45EE-B1A8-B4B0B097F007
wdt:P304
498-508
p:P31
wds:Q58204787-D456242A-CFC6-439D-BD68-EE483D6D6AEF
wdt:P31
wd:Q13442814
p:P921
wds:Q58204787-025C6988-448A-4B0E-BF56-B7DBA9564695 wds:Q58204787-039758DD-6DB9-4018-A8D8-582E89E21458 wds:Q58204787-60480079-C2A6-4DDE-A0A3-C4645BF237F4 wds:Q58204787-F304F4AA-C201-4A39-B7C3-6D88B24071B0
wdt:P921
wd:Q348260 wd:Q187255 wd:Q181600 wd:Q327657
p:P698
wds:Q58204787-96F87F96-8131-4D3E-B5F5-366C9F2E6F0E
wdtn:P698
n13:21993918
wdt:P698
21993918
p:P1433
wds:Q58204787-FFE252E1-B571-418B-9389-3AEF30823DD2
wdt:P1433
wd:Q15752709
p:P433
wds:Q58204787-B655CB83-DAA0-434C-A6F9-AAA7678AE3BA
p:P478
wds:Q58204787-C992771A-6457-4939-BE37-937AAF67E1E5
wdt:P433
4
wdt:P478
22
p:P356
wds:Q58204787-18EF495C-D41A-4F0F-AE2A-7BB7A9D95FDB
wdtn:P356
n11:S10165-011-0541-5
wdt:P356
10.1007/S10165-011-0541-5